Citra-Lock™S 4%

Citra-Lock 4% is recommended in the European Renal Best Practice Guidelines (ERBP) and the American Society of Diagnostic and Interventional Nephrology (ASDIN).

Citra locks have been extensively studied.
4% offers the best benefit/risk ratio.

Citra-Lock is effective in maintaining catheter patency.

Trisodium Citrate 4% (TSC) works as an anti-coagulant and decreases the incidence of infection.

Clinical advantage of Citra-Lock 4% (compared to heparine)

  • safe
  • avoids heparin-associated bleeding
  • improves reliability of INR assyas (prothrombin time – time/international normalised ratio)
  • safe for heparin induced thrombocytopenia (HIT patients)
  • no side effects
  • reduction of tPA use
  • better outcomes over catheter exchange
  • reduction of hospitalisation
  • cost efficient

Increase Safety & Simplified handling

Products

Citra-Gen develops, manufactures and sells innovative products for central venous access in the fields of renal therapy, hematology and oncology.

Citra-Gen™

Citra-Gen products are part of international recommended guidelines of today, defined by clinicians. Citra-Gen presents its products worldwide through a global network of dedicated distributors. Therefore, Citra-Gen is able to offer a high level of support to local customers.

Citra-Lock™ is recommended in the European Renal Best Practice Guidelines (ERBP) and the American Society of Diagnostic and Interventional Nephrology (ASDIN).

 — Citra-Lock™

Effective range of biocompatible catheters, prepared for state of the art blood flows.

 — Citra-XS™ Catheters